Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for the discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.
Kontrakty CFD to złożone instrumenty, które wiążą się z dużym ryzykiem gwałtownej straty środków na skutek zastosowania dźwigni finansowej. 70% inwestorów detalicznych odnotowuje straty w handlu kontraktami CFD z tym dostawcą. Powinieneś rozważyć, czy rozumiesz, jak działają kontrakty CFD i czy możesz sobie pozwolić na podjęcie wysokiego ryzyka utraty pieniędzy. Prosimy o zapoznanie się z naszym Oświadczeniem o ryzyku
Oceny i recenzje
Oceny i recenzje
